The first clinical trials exploring the efficacy and safety of the in vivo CLR-targeting approach in cancer started only about a decade ago and only a few of them were completed with published results (Table 1 and Table S1 (Supplementary Materials)). This evidence concerns the gene DCLK3 and cancer.